Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03784482
Other study ID # RECHMPL18_0478
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 20, 2018
Est. completion date July 31, 2019

Study information

Verified date November 2019
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Multiple drug hypersensitivity syndrome (MDH) is defined as confirmed drug hypersensitivity reactions (DHRs) to at least 2 chemically and pharmacologically unrelated drugs. Reports of MDH are scarce and poorly specified and studies which diagnose MDH on the basis of positive allergy tests are lacking.

Objective: To evaluate retrospectively the frequency and characteristics of MDH patients in a large database.

Methods: All the patients who consulted and were tested in our Allergy Unit between September 1996 and February 2018, with confirmed MDH will be included. Clinical history and allergy work-up results will be extracted from our Drug Allergy and Hypersensitivity Database (DAHD). The frequency of MDH will be calculated, MDH patients will be described, the most frequent associations of DHRs will be identified and analysed.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date July 31, 2019
Est. primary completion date June 30, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion criteria:

- Patients who consulted at our allergy clinic (University Hospital of Montpellier, France)

- Between September 1996 and February 2018 with a clinical history suggestive of DHR

- Who completed a tailored drug allergy work-up, (including a drug allergy questionnaire, skin tests (STs) and drug provocation tests (DPTs)) and were diagnosed with MDH.

Exclusion criteria:

- the DHR was due to a single component contained in 2 different drug formulations

- in composed drugs;

- there was possible cross-reactivity between the responsible drugs; (iv) the patient had positive but non standardized nor validated (i.e. possibly irritant)

- these STs were followed by a negative DPT;

- DPTs with placebo were positive; (vii) doubtful tests were repeated and eventually considered negative;

- a single DHR was associated with one or more non-drug related contact allergies;

- DPTs elicited subjective manifestations (i.e., isolated pruritus, headache, isolated abdominal pain);

- non-specific histamine release was suspected (e.g., chronic spontaneous - desensitization, rather than a diagnostic work-up was preferred in order to meet the urgent therapeutic needs of individual patients (HIV infected patients, cardiac patients).

Study Design


Locations

Country Name City State
France University hospital of Montpellier Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary To measure retrospectively the frequency of MDH patients in our database. The frequency of MDH patients (percentage) in the allergic group of patients will be calculated as the number of MDH patients divided by the number of monoallergic patients (frequency of MDH patients in allergic population) 1 day
Primary To measure retrospectively the frequency of MDH patients in our database The frequency of MDH in common population will be calculated by will be calculated as the number of MDH patients divided by the number of patients that underwent diagnostic drug allergy testing within the same time frame (frequency of MDH patients in the whole population 1 day
Secondary To describe the MDH population, identify the most frequent associations of DHR In this MDH patients population we will : Count the number of female and male patient according to their sex (No unit) 1 day
Secondary To describe the MDH population, identify the most frequent associations of DHR In this MDH patients population we will : Most frequent associations of DHR (No unit) 1 day
Secondary To describe the MDH population, identify the most frequent associations of DHR In this MDH patients population we will : Count and classify the different form of DHR according to their severity with the Ring and Messsmer and Regiscar study group scoring. (No unit) (ex: number of patient with grade III anaphylaxis or number of patient with DRESS syndrome ) 1 day
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06414694 - Inpatient Penicillin Delabeling for Low-Risk Patients Phase 4
Completed NCT05706246 - Perioperative Hypersensitivity in Children N/A
Recruiting NCT04920721 - Retrospective Study of Immediate Hypersensitivity (IHS) Reactions to Platinum Salts in the University Hospital of Nancy
Completed NCT02118987 - Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization Phase 1
Enrolling by invitation NCT03164044 - Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy
Completed NCT02094638 - Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study N/A
Not yet recruiting NCT06399601 - A Training Program of Drug Allergy for Healthcare Professionals N/A
Not yet recruiting NCT06406114 - Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing Phase 2
Recruiting NCT05820802 - High Dimensional Analysis of Immune Cells in Pediatric Patients